Last reviewed · How we verify

Alameda Health System — Portfolio Competitive Intelligence Brief

Alameda Health System pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ketamine IV Infusion Ketamine IV Infusion marketed
Ketamine IV push Ketamine IV push marketed NMDA receptor antagonist NMDA receptor Anesthesia, Pain Management, Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ajou University School of Medicine · 1 shared drug class
  2. American University of Beirut Medical Center · 1 shared drug class
  3. Asker & Baerum Hospital · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. Auris Medical AG · 1 shared drug class
  6. Beijing Tiantan Hospital · 1 shared drug class
  7. Celon Pharma SA · 1 shared drug class
  8. Acacia Pharma Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Alameda Health System:

Cite this brief

Drug Landscape (2026). Alameda Health System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alameda-health-system. Accessed 2026-05-16.

Related